AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Multimodal Biocollection Linked to the French Register of Intracranial Aneurysms

RecruitingNAAges 18 Years - anyAllNantes University Hospital
💬

In plain words

What the trial is, and whether it could suit you

The purpose of the bCAN study is to create a prospective collection of multimodal data and human samples, linked to the French Intracranial Aneurysm Registry (FRAN). The aim of bCAN is to enable risk stratification of ruptured ICAs by redefining "intracranial aneurysm disease". The description of genotypically and phenotypically specific subgroups of cases will pave the way for improved patient management based on new diagnostic/prognostic strategies among AIC carriers, either in a familial context, or at the level of the general population.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion criteria for sporadic ICA cases: * Any adult patient consulting for a definite and typical bifurcation AIC authenticated on MRI and/or cerebral arteriography * Aneurysm discovered less than a year ago, with initial imaging (MRI and/or CTA and DSA) available * Written consent obtained for study participation * Patient covered by a social security plan Inclusion criteria for index and related cases (familial forms) of intracranial aneurysms (ICA): * Index case: Any adult patient consulting for a definite and typical bifurcation ICA presenting at least one other case with ICA related (child, parent, brother, sister) detected by MRI with at least one Time of Flight (TOF) sequence. * Family relatives: children, parents, brothers, sisters, of legal age, of patients with a family history of definite, typical bifurcation AIC (≥ 4 affected), Screening to be performed using MRI with at least a Time of Flight (TOF) sequence. * Written consent to participate in the study * Patient and relatives covered by a social security plan Exclusion Criteria: * Syndromic diagnosis known to cause ICA: Marfan syndrome, OSA with SMAD 3, Elhers Danlos syndrome type II and IV, Autosomal Dominant Cystic Fibrosis, Moya-Moya syndrome * AIC with : Dissecting or fusiform, Associated with arteriovenous malformation, Blister-like, Mycotic * Cerebral white matter pathology detected on MRI evoking : Col4a1 mutation * Patient under guardianship or conservatorship * Person under court protection * Contraindication to an MRI scan
💊

What it tests

  • blood or saliva sample
📍

Where

26 sites
Nantes University Hospital
Nantes, France
CHU Amiens
Amiens, France
CHU Angers
Angers, France
CHU Besançon
Besançon, France
CHU Bordeaux Hôpital Pellegrin
Bordeaux, France
CHU de Brest
Brest, France
CHU Caen-Normandie
Caen, France
CHU Clermont-Ferrand
Clermont-Ferrand, France

…and 18 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy